Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study

NCT07534371 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: surufatinib
DRUG: Somatostatin Analogs

Sponsor

West China Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]